The NDFIP2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji B lymphocyte cell line, engineered to disrupt the NDFIP2 gene. This product provides a pooled population of cells carrying heterogeneous edits at the target locus, thereby avoiding artifacts associated with clonal selection and enabling studies in a genetically diverse knockout background. The disruption of NDFIP2 results in a loss-of-function model that can be employed to dissect the molecular roles of this adaptor protein in ubiquitin-dependent regulatory mechanisms.
The Raji cell line is a well-characterized human lymphoblastoid line originally established from a Burkitt lymphoma patient. As a B lymphocyte model, Raji cells retain features of mature B cells, including surface immunoglobulin expression and active intracellular signaling networks, making them a valuable system for investigating B-cell biology, lymphomagenesis, and immune responses. Their robust growth and genetic tractability have established Raji cells as a standard host for knockout studies in hematological malignancies.
NDFIP2 functions as a molecular adaptor that specifically recruits substrate proteins to NEDD4-family E3 ubiquitin ligases, such as NEDD4-1, NEDD4-2, ITCH, and WWP2, thereby facilitating ubiquitination and subsequent lysosomal or proteasomal degradation. Key downstream targets include the divalent metal transporter DMT1 and the epidermal growth factor receptor EGFR, whose degradation is tightly controlled to modulate endosomal trafficking and receptor signaling. NDFIP2 activity is influenced by upstream inputs from B-cell receptor signaling, cytokine receptors, and cellular stress stimuli, positioning it as a critical node connecting extracellular cues to endocytic sorting and protein homeostasis.
In the Raji B-cell context, NDFIP2-mediated regulation is particularly relevant for immune signaling and lymphomagenesis. By controlling the stability and trafficking of receptors and transporters, NDFIP2 influences pathways that govern B-cell activation, proliferation, and survival. Its disruption may alter the degradation of oncogenic or immunomodulatory substrates, potentially affecting sensitivity to proteasome inhibitors and other therapies commonly used in B-cell malignancies. Thus, this knockout model offers a physiologically relevant system to explore how ubiquitin-dependent processes sustain lymphoma cell biology.
Researchers can utilize these polyclonal knockout cells to investigate NDFIP2-dependent ubiquitination events, employing techniques such as co-immunoprecipitation with NEDD4 ligases, western blotting for DMT1 or EGFR, and ubiquitination assays to assess substrate modification. Flow cytometry can be applied to monitor surface marker expression, while cell viability and drug sensitivity testing (e.g., with proteasome inhibitors) can illuminate roles in drug resistance. This model is suitable for functional studies in immunology, cancer biology, and neuroinflammation. For further details, contact Ascent Research.
